In this July 8, 2016, file photo, a pharmacist holds a package of EpiPens epinephrine auto-injector, a Mylan product, in Sacramento, Calif. (AP Photo/Rich Pedroncelli, File) Congress is not done with Mylan. Top senators angered by the exorbitant cost of the EpiPen, produced by Mylan, are expanding their inquiry to federal health regulators to discern whether the drug company knowingly and improperly paid state Medicaid programs less than it should have. A spokeswoman for Chuck Grassley (R-Iowa), chairman of the Senate Judiciary Committee probing the high price of the life-saving EpiPen, said Thursday the senator plans to request documents from Mylan and the Center for Medicare & Medicaid Services about warnings the agency says it gave Mylan about incorrectly classifying EpiPen as a generic instead of a brand-name drug. That classification allowed the company to pay less in rebates to state Medicaid programs — but it is unclear exactly by how much. …
Go to Source
Congress expanding Mylan inquiry to determine if there was Medicaid fraud